CLRBZ - (Cellectar Biosciences Inc.)

 CLRBZのチャート


 CLRBZの企業情報

symbol CLRBZ
会社名
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種   
概要 事業概要 --     
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/clrbz
adr_tso
EBITDA EBITDA ー
終値(lastsale) 0.0801
時価総額(marketcap) 0
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 CLRBZのテクニカル分析


 CLRBZのニュース

   28 Stocks Moving in Tuesday's Pre-Market Session  2021/03/16 11:44:06 Benzinga
Gainers SunLink Health Systems, Inc. (NYSE: SSY ) shares rose 82.4% to $3.52 in pre-market trading as the company reported $2 million expansion, capital and operating improvements at Trace Regional Hospital. NTN Buzztime, Inc. (NYSE: NTN ) rose 50.1% to $5.66 in pre-market trading. NTN Buzztime said its stockholders approved the proposed merger between NTN and Brooklyn ImmunoTherapeutics LLC. Sypris Solutions, Inc. (NASDAQ: SYPR ) rose 46.9% to $5.51 in pre-market trading. Sypris Solutions is expected to release Q4 earnings on March 18. Anchiano Therapeutics Ltd. (NASDAQ: ANCN ) rose 43.2% to $6.40 in pre-market trading after the company reported shareholder approval of the merger with Chemomab. The company also priced its $45.5 million private financing. Enzo Biochem, Inc. (NYSE: ENZ ) shares rose 36.4% to $4.04 in pre-market trading after the company swung to a profit in the second quarter. Savara Inc. (NASDAQ: SVRA ) rose 30% to $2.30 in pre-market trading after the company's CFO disclosed an open market purchase of 13,793 shares at $1.45 per share.
   Pediatric Neuroblastoma Treatment Market to Rapidly Growing in Healthcare Sector with Top Key Players: United Therapeutics Corporation, APEIRON Biologics AG, Baxter, CELLECTAR BIOSCIENCES, INC, Sun Pharmaceutical Industries, Pfizer, Bayer AG, MacroGenics  2020/11/25 14:04:57 OpenPR
The Pediatric Neuroblastoma Treatment Market studied was projected to grow with a CAGR of nearly +6% over the forecast period. As per the scope of the report neuroblastoma is cancer that develops from immature nerve cells found in several areas of
   Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - Stocks News Feed  2020/11/09 13:44:00 Stocks News Feed
FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. Third Quarter and Recent Corporate Highlights… Read More »Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
   Cellectar Biosciences (NASDAQ:CLRB) Stock Crosses Above 50-Day Moving Average of $1.20  2020/10/24 15:58:43 The Olympia Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares changing hands. Several analysts have recently weighed in on CLRB […]
   Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Above Fifty Day Moving Average of $1.20  2020/10/23 02:20:41 US Banking News
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares traded. Several analysts have weighed in on the […]
   Pediatric Neuroblastoma Treatment Market to Rapidly Growing in Healthcare Sector with Top Key Players: United Therapeutics Corporation, APEIRON Biologics AG, Baxter, CELLECTAR BIOSCIENCES, INC, Sun Pharmaceutical Industries, Pfizer, Bayer AG, MacroGenics  2020/11/25 14:04:57 OpenPR
The Pediatric Neuroblastoma Treatment Market studied was projected to grow with a CAGR of nearly +6% over the forecast period. As per the scope of the report neuroblastoma is cancer that develops from immature nerve cells found in several areas of
   Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - Stocks News Feed  2020/11/09 13:44:00 Stocks News Feed
FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. Third Quarter and Recent Corporate Highlights… Read More »Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
   Cellectar Biosciences (NASDAQ:CLRB) Stock Crosses Above 50-Day Moving Average of $1.20  2020/10/24 15:58:43 The Olympia Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares changing hands. Several analysts have recently weighed in on CLRB […]
   Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Above Fifty Day Moving Average of $1.20  2020/10/23 02:20:41 US Banking News
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares traded. Several analysts have weighed in on the […]
   Neuroblastoma Drug Market Demand, Growth Opportunities and Top Key Players Analysis- Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Baxter  2020/10/13 18:38:59 OpenPR
The large-scale Global Neuroblastoma Drug Market report provides details about market trends, future prospects, market restraints, leading market drivers, several market segments, key developments, key players in the market, and competitor strategies. This market study encompasses a market attractiveness analysis, wherein all
   Pediatric Neuroblastoma Treatment Market to Rapidly Growing in Healthcare Sector with Top Key Players: United Therapeutics Corporation, APEIRON Biologics AG, Baxter, CELLECTAR BIOSCIENCES, INC, Sun Pharmaceutical Industries, Pfizer, Bayer AG, MacroGenics  2020/11/25 14:04:57 OpenPR
The Pediatric Neuroblastoma Treatment Market studied was projected to grow with a CAGR of nearly +6% over the forecast period. As per the scope of the report neuroblastoma is cancer that develops from immature nerve cells found in several areas of
   Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - Stocks News Feed  2020/11/09 13:44:00 Stocks News Feed
FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. Third Quarter and Recent Corporate Highlights… Read More »Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
   Cellectar Biosciences (NASDAQ:CLRB) Stock Crosses Above 50-Day Moving Average of $1.20  2020/10/24 15:58:43 The Olympia Report
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares changing hands. Several analysts have recently weighed in on CLRB […]
   Cellectar Biosciences (NASDAQ:CLRB) Stock Price Passes Above Fifty Day Moving Average of $1.20  2020/10/23 02:20:41 US Banking News
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s share price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.20 and traded as high as $1.24. Cellectar Biosciences shares last traded at $1.20, with a volume of 115,859 shares traded. Several analysts have weighed in on the […]
   Neuroblastoma Drug Market Demand, Growth Opportunities and Top Key Players Analysis- Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Baxter  2020/10/13 18:38:59 OpenPR
The large-scale Global Neuroblastoma Drug Market report provides details about market trends, future prospects, market restraints, leading market drivers, several market segments, key developments, key players in the market, and competitor strategies. This market study encompasses a market attractiveness analysis, wherein all

 関連キーワード  (― 米国株 CLRBZ Cellectar Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)